HCC Best Practice: Suspected Immunodeficiency to Drugs
Immunodeficiency to drugs
The trigger criteria is:
- Has active med from grouper -OHS RX IMMUNOSUPPRESSANTS 2 [480000117] (See Below)
- Is not a Transplant Patient
- ABATACEPT
- ABATACEPT/MALTOSE
- ACALABRUTINIB
- ADALIMUMAB
- APREMILAST
- AZATHIOPRINE
- BORTEZOMIB
- CAPECITABINE
- CARBOPLATIN
- CISPLATIN
- CYCLOPHOSPHAMIDE
- DECITABINE/CEDAZURIDINE
- DIMETHYL FUMARATE
- DOCETAXEL
- DOXORUBICIN HCL
- ETOPOSIDE
- EVEROLIMUS
- FLUOROURACIL
- GEMCITABINE HCL
- GEMCITABINE HCL IN 0.9 % NACL
- HYDROXYCHLOROQUINE SULFATE
- HYDROXYUREA
- IBRUTINIB
- IDELALISIB
- IMATINIB MESYLATE
- LEFLUNOMIDE
- LENALIDOMIDE
- MERCAPTOPURINE
- METHOTREXATE SODIUM
- MYCOPHENOLATE MOFETIL
- MYCOPHENOLATE MOFETIL HCL
- MYCOPHENOLATE SODIUM
- PACLITAXEL
- PACLITAXEL PROTEIN-BOUND
- PALBOCICLIB
- RITUXIMAB
- RUXOLITINIB PHOSPHATE
- SULFASALAZINE
- TACROLIMUS
- TEMOZOLOMIDE
- TOCILIZUMAB
- USTEKINUMAB
Two new Suspect Best Practice Advisories (BPAs) were implemented into the Hierarchical Coding Category (HCC) BPA tool in Ochsner’s instance of Epic this month. Additionally, CDE Query is now in the BPA window. Click here for the updated workflow.
